Erratum: Randomised trials of human albumin for adults with sepsis: Systematic review and meta-analysis with trial sequential analysis of all-cause mortality (BMJ (2014) 349 (g4561) DOI: 10.1136/bmj.g4561);Randomised trials of human albumin for adults with sepsis: Systematic review and meta-analysis with trial sequential analysis of all-cause mortality

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Patel, Amit ^a   Laffan, Michael A ^a   Waheed, Umeer ^a   Brett, Stephen J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN ALBUMIN; CRYSTALLOID; ISOTONIC SOLUTION; SERUM ALBUMIN;

ADULT; CRYSTALLOID; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FLUID RESUSCITATION; FOLLOW UP; HUMAN; HYPOALBUMINEMIA; INTENSIVE CARE UNIT; INTERSTITIAL FLUID; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; REVIEW; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ANALYSIS; SYSTEMATIC REVIEW; FLUID THERAPY; PROCEDURES; RESUSCITATION;

FLUID THERAPY; HUMANS; HYPOALBUMINEMIA; INTENSIVE CARE UNITS; ISOTONIC SOLUTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESUSCITATION; SEPSIS; SERUM ALBUMIN;

EID: 84904581827     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g4850     Document Type: Erratum

References (127)

1. Bunn F, Trivedi D. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev 2012;7:CD001319.
2. Jacob M, Chappell D, Conzen P, Wilkes MM, Becker BF, Rehm M. Small-volume resuscitation with hyperoncotic albumin: a systematic review of randomized clinical trials. Crit Care 2008;12:R34.
3. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2013;2:CD000567.
4. Roberts I, Blackhall K, Alderson P, Bunn F, Schierhout G. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev 2011;(11):CD001208.
5. Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D, et al; SAFE TRIPS Investigators. Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units. Crit Care 2010;14:R185.
6. Yim JM, Vermeulen LC, Erstad BL, Matuszewski KA, Burnett DA, Vlasses PH. Albumin and nonprotein colloid solution use in US academic health centers. Arch Intern Med 1995;155:2450-5.
7. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-56.
8. Finfer S, McEvoy S, Bellomo R, McArthur C, Myburgh J, Norton R; SAFE Study Investigators. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med 2011;37:86-96.
9. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al; Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006;34:344-53.
10. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-64.
11. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-87.
12. Intravenous fluid therapy in adults in hospital. NICE clinical guideline 174 2013 (December): www.nice.org.uk/nicemedia/live/14330/66015/15.pdf.
13. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228. doi:10.1007/s00134-012-2769-8.
14. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
15. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
16. Christopher KB, Reed GW, Nurok M, Moromizato T, Gibbons FK, Topulos GP. Change of serum albumin and risk of all-cause mortality in critical illness: a cohort study. Intensive Care Med 2012;38(suppl 1):1.
17. Artero A, Zaragoza R, Camarena JJ, Sancho S, González R, Nogueira JM. Prognostic factors of mortality in patients with community-acquired bloodstream infection with severe sepsis and septic shock. J Crit Care 2010;25:276-81.
18. Guidet B, Mosqueda GJ, Priol G, Aegerter P. The COASST study: cost-effectiveness of albumin in severe sepsis and septic shock. J Crit Care 2007;22:197-203.
19. Dubois MJ, Orellana-Jimenez C, Melot C, De Backer D, Berre J, Leeman M, et al. Albumin administration improves organ function in critically ill hypoalbuminemic patients: A prospective, randomized, controlled, pilot study. Crit Care Med 2006;34:2536-40.
20. Finfer S, Bellomo R, McEvoy S, Lo SK, Myburgh J, Neal B, et al; SAFE Study Investigators. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ 2006;333:1044.
21. Goldwasser P, Feldman J. Association of serum albumin and mortality risk. J Clin Epidemiol 1997;50:693-703.
22. Delaney AP, Dan A, McCaffrey J, Finfer S. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med 2011;39:386-91.
23. Sterne JA, Davey Smith G. Sifting the evidence-what's wrong with significance tests? BMJ 2001;322:226-31.
24. Administration UFaD. FDA Safety Communication: Boxed Warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings. 2013. www.fda.gov/biologicsbloodvaccines/safetyavailability/ucm358271.htm.
25. Agency EM. Hydroxyethyl-starch solutions (HES) no longer to be used in patients with sepsis or burn injuries or in critically ill patients. EMA/809470/2013 2013. www.ema.europa.eu/docs/en-GB/document-library/Referrals- document/Solutions-for-infusion-containing-hydroxyethyl-starch/ European-Commission-final-decision/WC500162361.pdf.
26. Patel A, Waheed U, Brett SJ. Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis. Intensive Care Med 2013;39:811-22.
27. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, et al; 6S Trial Group; Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012;367:124-34.
28. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001;357:911-6.
29. Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S; CHEST Management Committee. Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 2013;39:558-68.
30. Wiedermann CJ, Joannidis M. Increased mortality after infusion of "modern" hydroxyethyl starch. Swiss Med Wkly 2013;143:w13747.
31. Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 2013;309:678-88.
32. Wise J. Boldt: the great pretender. BMJ 2013;346:f1738.
33. Editors in chief statement regarding published clinical trials conducted without IRB approval by Joachim Boldt. 2011. www.aaeditor.org/EIC.Joint. Statement.on.Retractions.pdf.
34. Hospital L. Hospital Presents Results of Final Report: Committee Completes Investigation in the Case of Dr Boldt. 2012. www.klilu.de/content/ veranstaltungen-presse/pressearchiv/2012/hospital-presents-results-of-final- report-committee-completes-investigation-in-the-case-of-dr-boldt/index-ger.html.
35. Leitch A, Craig G, Sadler P. Human albumin solution resuscitation in severe sepsis and septic shock. J Intensive Care Soc 2013;14:45-52.
36. Farrugia A, Bansal M, Balboni S, Kimber MC, Martin GS, Cassar J. Choice of fluids in severe septic patients - a cost-effectiveness analysis informed by recent clinical trials. Rev Recent Clin Trials 2013;9:21-30.
37. Charpentier J, Mira JP, Group ES. Efficacy and tolerance of hyperoncotic albumin administration in septic shock patients: the EARSS study. Intensive Care Med 2011;37(suppl 1):S115.
38. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, et al; ALBIOS Study Investigators. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014;370:1412-21.
39. Cohen J, Guyatt G, Bernard GR, Calandra T, Cook D, Elbourne D, et al; UK Medical Research Council International Working Party. New strategies for clinical trials in patients with sepsis and septic shock. Crit Care Med 2001;29:880-6.
40. .American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
41. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Cochrane Collaboration, 2011.
42. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
43. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
44. Cook DJ, Guyatt GH, Ryan G, Clifton J, Buckingham L, Willan A, et al. Should unpublished data be included in meta-analyses? Current convictions and controversies. JAMA 1993;269:2749-53.
45. Panagiotou OA, Contopoulos-Ioannidis DG, Ioannidis JP, Rehnborg CF. Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment. BMJ 2013;346:f707.
46. Onwuegbuzie AJ, Leech NL. Post hoc power: A concept whose time has come. Underst Stat 2004;3:201-30.
47. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
48. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
49. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-63.
50. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al; ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307:2526-33.
51. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
52. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119-29.
53. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ; GRADE Working Group. What is "quality of evidence" and why is it important to clinicians?. BMJ 2008;336:995-8.
54. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559-73.
55. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ 2013;346:f2304.
56. Zhang Z, Xu X, Ni H. Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study. Crit Care 2013;17:R2.
57. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al; The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-55.
58. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al; ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 2009;136(suppl):e28.
59. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, et al. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 2013;346:f839.
60. Wiedermann CJ, Dunzendorfer S, Gaioni LU, Zaraca F, Joannidis M. Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. Crit Care 2010;14:R191.
61. Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declère AD, et al; CRISTAL Investigators. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA 2013;310:1809-17.
62. Thomas-Rueddel DO, Vlasakov V, Reinhart K, Jaeschke R, Rueddel H, Hutagalung R, et al. Safety of gelatin for volume resuscitation--a systematic review and meta-analysis. Intensive Care Med 2012;38:1134-42.
63. Patel A, Brett SJ. Gelatin solutions for critically unwell septic adults. Br J Hosp Med (Lond) 2013;74:657.
64. Cohen IL. Guidelines for the use of innovative therapies in sepsis. Crit Care Med 1993;21:476-7.
65. Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM. Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Ann Surg 2003;237:319-34.
66. Vincent JL, Navickis RJ, Wilkes MM. Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials. Crit Care Med 2004;32:2029-38.
67. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
68. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
69. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
70. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. Int J Epidemiol 2009;38:276-86.
71. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA). Copenhagen Trial Unit. Centre for Clinical Intervention Research, 2011.
72. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008;61:64-75.
73. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol 2009;9:86.
74. Boldt J, Heesen M, Müller M, Pabsdorf M, Hempelmann G. The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically ill patients. Anesth Analg 1996;83:254-61.
75. Boldt J, Heesen M, Welters I, Padberg W, Martin K, Hempelmann G. Does the type of volume therapy influence endothelial-related coagulation in the critically ill? Br J Anaesth 1995;75:740-6.
76. Boldt J, Müller M, Heesen M, Heyn O, Hempelmann G. Influence of different volume therapies on platelet function in the critically ill. Intensive Care Med 1996;22:1075-81.
77. Boldt J, Muller M, Heesen M, Neumann K, Hempelmann GG. Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients. Crit Care Med 1996;24:385-91.
78. Dolecek M, Svoboda P, Kantorová I, Scheer P, Sas I, Bíbrová J, et al. Therapeutic influence of 20% albumin versus 6% hydroxyethylstarch on extravascular lung water in septic patients: a randomized controlled trial. Hepatogastroenterology 2009;56:1622-8.
79. Friedman G, Jankowski S, Shahla M, Gomez J, Vincent JL. Hemodynamic effects of 6% and 10% hydroxyethyl starch solutions versus 4% albumin solution in septic patients. J Clin Anesth 2008;20:528-33.
80. Haupt MT, Rackow EC. Colloid osmotic pressure and fluid resuscitation with hetastarch, albumin, and saline solutions. Crit Care Med 1982;10:159-62.
81. Metildi LA, Shackford SR, Virgilio RW, Peters RM. Crystalloid versus colloid in fluid resuscitation of patients with severe pulmonary insufficiency. Surg Gynecol Obstet 1984;158:207-12.
82. Palumbo D, Servillo G, D'Amato L, Volpe ML, Capogrosso G, De Robertis E, et al. The effects of hydroxyethyl starch solution in critically ill patients. Minerva Anestesiol 2006;72:655-64.
83. Rackow EC, Falk JL, Fein IA, Siegel JS, Packman MI, Haupt MT, et al. Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med 1983;11:839-50.
84. Rackow EC, Mecher C, Astiz ME, Griffel M, Falk JL, Weil MH. Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion. Crit Care Med 1989;17:394-8.
85. Trof RJ, Sukul SP, Twisk JW, Girbes AR, Groeneveld AB. Greater cardiac response of colloid than saline fluid loading in septic and non-septic critically ill patients with clinical hypovolaemia. Intensive Care Med 2010;36:697-701.
86. van der Heijden M, Verheij J, van Nieuw Amerongen GP, Groeneveld AB. Crystalloid or colloid fluid loading and pulmonary permeability, edema, and injury in septic and nonseptic critically ill patients with hypovolemia. Crit Care Med 2009;37:1275-81.
87. Veneman TF, Oude Nijhuis J, Woittiez AJ. Human albumin and starch administration in critically ill patients: a prospective randomized clinical trial. Wien Klin Wochenschr 2004;116:305-9.
88. Bulanov AIu, Gorodetskiǐ VM, Shulutko EM, Vasil'ev SA, Orel EB, Malofeev VN, et al. [Effect of different colloid volume-replacing solutions on a changed hemostasis system]. Anesteziol Reanimatol 2004;(2):25-30.
89. Ernest D, Belzberg AS, Dodek PM. Distribution of normal saline and 5% albumin infusions in septic patients. Crit Care Med 1999;27:46-50.
90. Falk JL, Rackow EC, Astiz ME, Weil MH. Effects of hetastarch and albumin on coagulation in patients with septic shock. J Clin Pharmacol 1988;28:412-5.
91. Foley EF, Borlase BC, Dzik WH, Bistrian BR, Benotti PN. Albumin supplementation in the critically ill. A prospective, randomized trial. Arch Surg 1990;125:739-42.
92. Golub R, Sorrento JJ Jr, Cantu R Jr, Nierman DM, Moideen A, Stein HD. Efficacy of albumin supplementation in the surgical intensive care unit: a prospective, randomized study. Crit Care Med 1994;22:613-9.
93. Gondos T, Marjanek Z, Ulakcsai Z, Szabó Z, Bogár L, Károlyi M, et al. Short-term effectiveness of different volume replacement therapies in postoperative hypovolaemic patients. Eur J Anaesthesiol 2010;27:794-800.
94. Hondebrink Y, Jeekel L, Oude Nijhuis J, Woittiez AJJ. Restoration of colloid osmotic pressure in hypoalbuminaemic patients. Intensive Care Med 1997;23(supplement 1):S184.
95. Martin GS, Mangialardi RJ, Wheeler AP, Dupont WD, Morris JA, Bernard GR. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit Care Med 2002;30:2175-82.
96. Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA, Bernard GR. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med 2005;33:1681-7.
97. McIntyre LA, Fergusson DA, Cook DJ, Rowe BH, Bagshaw SM, Easton D, et al; Canadian Critical Care Trials Group. Fluid Resuscitation with 5% albumin versus Normal Saline in Early Septic Shock: a pilot randomized, controlled trial. J Crit Care 2012;27:e1-6.
98. Quinlan GJ, Mumby S, Martin GS, Bernard GR, Gutteridge JM, Evans TW. Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med 2004;32:755-9.
99. Rubin H, Carlson S, DeMeo M, Ganger D, Craig RM. Randomized, double-blind study of intravenous human albumin in hypoalbuminemic patients receiving total parenteral nutrition. Crit Care Med 1997;25:249-52.
100. Stockwell MA, Scott A, Day A, Riley B, Soni N. Colloid solutions in the critically ill. A randomised comparison of albumin and polygeline 2. Serum albumin concentration and incidences of pulmonary oedema and acute renal failure. Anaesthesia 1992;47:7-9.
101. Stockwell MA, Soni N, Riley B. Colloid solutions in the critically ill. A randomised comparison of albumin and polygeline. 1. Outcome and duration of stay in the intensive care unit. Anaesthesia 1992;47:3-6.
102. Verheij J, van Lingen A, Beishuizen A, Christiaans HM, de Jong JR, Girbes AR, et al. Cardiac response is greater for colloid than saline fluid loading after cardiac or vascular surgery. Intensive Care Med 2006;32:1030-8.
103. Wojtysiak SL, Brown RO, Roberson D, Powers DA, Kudsk KA. Effect of hypoalbuminemia and parenteral nutrition on free water excretion and electrolyte-free water resorption. Crit Care Med 1992;20:164-9.
104. Finfer S, Norton R, Bellomo R, Boyce N, French J, Myburgh J. The SAFE study: saline vs. albumin for fluid resuscitation in the critically ill. Vox Sang 2004;87(Suppl 2):123-31.
105. Mayr W, Prowse C. Retraction: Finfer S, Norton R, Bellomo R, Boyce N, French J, Myburch J, on behalf of the SAFE Study Investigators. The SAFE study: saline vs. albumin for fluid resuscitation in the critically ill. Vox Sang 2004; 87 (Suppl. 2): S123-31. 2004;87:142.
106. Timmer B, Hondebrink J, Oude Nijhuis J, Woittiez AJ. Restoration of colloid osmotic pressure in hypoalbuminaemic patients. Neth J Med 1998;52:A42.
107. Almeida A, Martin G, Hajjar L. Lactated Ringer Versus Albumin in Early Sepsis Therapy (RASP). 2013. http://clinicaltrials.gov/ct2/show/NCT01337934.
108. Wang Y, An YZ, Ma PL; China Critical Care Clinical Trial Group. Albumin for fluid resuscitation in patients with sepsis: what do we expect for? Chin Med J (Engl) 2013;126:3379-82.
109. Bansal M, Farrugia A, Balboni S, Martin G. Relative survival benefit and morbidity with fluids in severe sepsis - a network meta-analysis of alternative therapies. Curr Drug Saf 2013;8:236-45.
110. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al; Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73.
111. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004;30:536-55.
112. Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 2013;11:123-30.
113. Cui JY, Xu HL, Wang AT, Zhu X, Yao GQ, Liu F. [Influence of albumin as a resuscitation fluid on the prognosis of patients with sepsis: a Meta-analysis]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2012;24:18-23.
114. Thompson SG. Systematic review - why sources of heterogeneity in metaanalysis should be investigated. BMJ 1994;309:1351-5.
115. Schortgen F, Girou E, Deye N, Brochard L; CRYCO Study Group. The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 2008;34:2157-68.
116. LeLorier J, Grégoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536-42.
117. Vincent JL, Wilkes MM, Navickis RJ. Safety of human albumin - serious adverse events reported worldwide in 1998-2000. Br J Anaesth 2003;91:625-30.
118. von Hoegen I, Waller C. Safety of human albumin based on spontaneously reported serious adverse events. Crit Care Med 2001;29:994-6.
119. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999;39:1160-8.
120. Boldt J, Muller M, Mentges D, Papsdorf M, Hempelmann G. Retraction note: Volume therapy in the critically ill: is there a difference? Intensive Care Med 2014;40:145.
121. .Notice of formal retraction of an article by Dr Joachim Boldt. Br J Anaesth 2014;112:397.
122. Hartog CS, Brunkhorst FM, Bloos F, Bogatsch H, Engel C, Sengebusch K, et al. Practice of volume therapy in patients with severe sepsis: results from a nationwide sepsis prevalence study. Intensive Care Med 2010;36:553-4.
123. Quinlan GJ, Margarson MP, Mumby S, Evans TW, Gutteridge JM. Administration of albumin to patients with sepsis syndrome: a possible beneficial role in plasma thiol repletion. Clin Sci (Lond) 1998;95:459-65.
124. British National Formulary (BNF) . 65 ed. BMJ Group, Pharmaceutical Press, 2013.
125. Bar-Or D, Bar-Or R, Rael LT, Gardner DK, Slone DS, Craun ML. Heterogeneity and oxidation status of commercial human albumin preparations in clinical use. Crit Care Med 2005;33:1638-41.
126. Matejtschuk P, Dash CH, Gascoigne EW. Production of human albumin solution: a continually developing colloid. Br J Anaesth 2000;85:887-95.
127. McIntyre L, Fergusson DA, Rowe B, Cook DJ, Arabi Y, Bagshaw SM, et al; Canadian Critical Care Trials Group. The PRECISE RCT: evolution of an early septic shock fluid resuscitation trial. Transfus Med Rev 2012;26:333-41.